Bevacizumab, Fluorouracil, Leucovorin, Oxaliplatin, Cetuximab, Irinotecan, 5-Fu, Petosemtamab, Mcla-158
Colorectal Cancer
Phase III
Recruiting
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)
Aug 13, 2026
―
Gemcitabine, Paclitaxel, Pegylated Liposomal Doxorubicin, Topotecan, Rina-S
Platinum-Resistant Ovarian Cancer
Phase III
Recruiting
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China
May 18, 2026
Carboplatin, Bevacizumab, Gemcitabine, Paclitaxel, Pld, Rina-S
Platinum-sensitive Ovarian Cancer, Ovarian Cancer
Phase III
Recruiting
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
Apr 27, 2026
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Genmab A/S (GE91) have in its pipeline
GE91 is currently developing the following drugs: Bevacizumab, Fluorouracil, Leucovorin, Oxaliplatin, Cetuximab, Irinotecan, 5-Fu, Petosemtamab, Mcla-158, Cetuximab, Folfiri, Mfolfox6, Petosemtamab, Gen1119. These drug candidates are in various stages of clinical development as the company works toward FDA approval.